stockrow
Saturday 7 November 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024.
- Revenue
- +4,895.9%
- EPS
- +426.5%
- Free cash flow
- +25.7%
- Total debt
- +3.27%
Quarter to September 2026, against a year earlier
2.30
0.21
+10.05%
Follow ALEC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 5.29 |
P/S ratio |
7.64 | 12.91 | 16.13 | 1.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.85) | (4.77) | (6.53) | (8.61) | |
P/B ratio |
5.24 | 22.90 | 0.00 | 1.79 | |
Price to Tangible BV |
5.24 | 22.90 | 0.00 | 1.79 | |
EV/Sales |
(4.07) | 2.23 | 4.97 | 0.50 | |
EV/EBITDA |
0.56 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.47 | (0.24) | (0.44) | (0.58) | |
EV/FCF |
0.47 | (0.24) | (0.43) | (0.58) | |
Quick Ratio |
3.68 | 5.04 | 5.05 | 3.92 | |
Current Ratio |
3.83 | 5.25 | 5.26 | 4.10 | |
Net Debt/EBITDA |
6.40 | 8.40 | 7.16 | 0.00 | |
Debt/Assets |
3.30% | 4.07% | 4.85% | 0.00% | |
Debt/Equity |
0.32 | 0.94 | (0.99) | 0.00 | |
Asset Turnover |
0.06 | 0.06 | 0.05 | 0.69 | |
Operating CF/Net income |
1.12 | 2.17 | 1.49 | (0.19) | |
Capex/Depreciation |
0.00 | (0.08) | (0.02) | — | |
Research and Development Expense of Revenue |
520.49% | 1,707.17% | 586.14% | 18.44% | |
Selling, General and Administrative Expense of Revenue |
213.88% | 775.14% | 248.58% | 5.52% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
77.65% | 278.01% | 78.61% | 1.23% | |
Graham Net Nets |
0.02 | (0.06) | (0.15) | 0.46 | |
Graham Number |
0.00 | 0.00 | 1.49 | 2.86 | |
Earnings Yield |
(89.10%) | (55.35%) | (54.73%) | 18.92% | |
Free Cash Flow Yield |
(114.56%) | (72.84%) | (70.85%) | (72.10%) | |
Revenue per Share |
0.06 | 0.01 | 0.03 | 1.45 | |
Operating CF per Share |
(0.40) | (0.45) | (0.31) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.45) | (0.31) | (0.21) | |
Cash per Share |
2.49 | 1.87 | 1.55 | 1.23 | |
Shareholders Equity per Share |
0.30 | 0.09 | (0.09) | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.30 | 0.09 | (0.09) | 1.04 | |
Free Cash Flow |
(41.69) | (49.93) | (34.25) | (24.15) | |
Working Capital |
196.95 | 174.12 | 145.85 | 109.93 | |
Capital Expenditures |
0.00 | (0.12) | (0.03) | — | |
Net Current Asset Value |
3.86 | (14.45) | (32.74) | 96.14 | |
EV/EBIT |
0.55 | 0.00 | 0.00 | 2.50 | |
Capex to Sales |
0.00 | 0.11 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 5.95 | |
| Other line items | |||||
Average Payables |
1.95 | 1.87 | 2.25 | 2.95 | |
Average Assets |
380.77 | 324.11 | 279.64 | 250.53 | |
Average Common Equity |
78.72 | 52.50 | 30.60 | 87.14 |
Columns are period end dates · fundamentals updated 5 Nov 2026